Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPoolbeg Pharma PLC

Poolbeg Pharma PLC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0958 USD 0.00(0%)
Last update at 2026-11-05T21:00:00Z
VOLUME
10000
Market Cap
73.14M

Momentum Score

…

Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is based in London, United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.10
Low
0.10
High
52 Week Price Range
0.04
Low
0.12
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.10
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-63.72%
Net Debt
-7.71M
ROCE
-74.62%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -5.77M -5.94M -4.50M -4.78M -2.34M
Net income -5.69M -5.79M -3.93M -4.69M -2.34M
Selling general administrative 4.89M 5.26M 3.38M 3.06M 2.03M
Selling and marketing expenses - - 3.35M - -
Gross profit -0.06M 0.00M -0.03M 0.00M 0.00M
Reconciled depreciation 0.06M 0.11M 0.03M 0.03M 0.02M
Ebit -6.42M -6.11M -4.69M -4.99M -2.34M
Ebitda -6.36M -6.00M -4.66M -4.96M -2.32M
Depreciation and amortization 0.06M 0.11M 0.03M 0.03M 0.02M
Operating income -6.42M -6.37M -5.04M -4.99M -2.34M
Other operating expenses 6.42M 6.37M 5.04M 4.99M 2.34M
Interest expense - - - - 0.00M
Tax provision -0.08M -0.15M -0.57M -0.09M 0.00M
Interest income 0.25M 0.43M 0.53M 0.21M 0.00M
Net interest income 0.25M 0.43M 0.53M 0.21M 0.00M
Income tax expense -0.08M 0.15M -0.57M -0.09M -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 6.35M 6.37M 5.04M 4.99M 2.34M
Cost of revenue 0.06M 0.00M 0.03M 0.00M 0.00M
Total other income expense net 0.64M 0.43M 0.53M 0.21M -
Net income from continuing ops -5.70M -5.79M -3.93M -4.69M -2.34M
Net income applicable to common shares - - - -4.69M -3.11M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 9.94M 10.25M 15.43M 19.29M 23.02M
Intangible assets 1.67M 1.68M 1.93M 2.13M 1.56M
Other current assets 0.19M 0.22M 0.63M - -
Total liab 1.34M 0.97M 0.99M 0.97M 0.44M
Total stockholder equity 8.60M 9.27M 14.44M 18.32M 22.58M
Other current liab 1.19M 0.74M 0.85M - 0.00M
Common stock 0.14M 0.10M 0.10M 0.10M 0.10M
Capital stock 0.14M 0.10M 0.10M 0.10M 0.10M
Retained earnings -20.98M -16.74M -10.95M -7.02M -2.34M
Other assets - - 0.00M - -
Cash 7.71M 7.82M 12.17M 16.19M 20.95M
Total current liabilities 1.34M 0.97M 0.99M 0.97M 0.44M
Net debt -7.71M -7.82M -12.17M -16.19M -20.95M
Other stockholder equity 27.53M 25.92M 23.10M 25.25M 24.82M
Total current assets 8.27M 8.56M 13.50M 17.16M 21.45M
Net tangible assets - - - 16.19M 21.02M
Net receivables 0.36M 0.52M 0.70M 0.96M 0.06M
Inventory - - -1.33M - -
Accounts payable 0.15M 0.17M 0.08M 0.97M 0.44M
Accumulated other comprehensive income 1.91M 1.70M 2.19M - -
Non currrent assets other - - 1.93M - -
Non current assets total 1.67M 1.68M 1.93M 2.13M 1.56M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.30M 0.36M -0.39M -0.08M
Change to liabilities - - - 0.53M 0.58M
Total cashflows from investing activities -0.08M 0.30M 0.36M -0.39M -0.11M
Total cash from financing activities 4.48M - - - 23.18M
Net income -5.69M -5.94M -3.93M -4.78M -2.34M
Change in cash 0.45M -4.35M -4.02M -4.76M 20.95M
Begin period cash flow 7.26M 12.17M 16.19M 20.95M 0.00M
End period cash flow 7.71M 7.82M 12.17M 16.19M 20.95M
Total cash from operating activities -4.51M -4.65M -4.38M -4.37M -2.15M
Issuance of capital stock 4.48M 0.00M - 0.00M 23.18M
Depreciation 0.06M 0.11M 0.03M 0.03M 0.02M
Other cashflows from investing activities 0.25M 0.43M 0.36M 0.21M 0.21M
Change to account receivables 0.19M 0.15M 0.00M -0.46M -0.67M
Other cashflows from financing activities - - 0.36M -0.39M 0.23M
Change to netincome - - - 0.22M 0.32M
Capital expenditures 4.51M 0.13M 0.17M 0.60M 0.08M
Change in working capital 0.56M 0.14M 0.00M 0.07M -0.07M
Stock based compensation 0.55M 0.62M 0.00M 0.43M 0.24M
Other non cash items 0.03M 0.43M -0.48M -0.12M -
Free cash flow -4.84M -4.78M -4.02M -4.96M -2.23M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
POLBF
Poolbeg Pharma PLC		 -
-%		 0.10 - - - 6.29 -9.01
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Poolbeg Pharma PLC

Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is based in London, United Kingdom.

The Clubhouse Holborn, London, United Kingdom, EC4A 3AG

44 20 7183 1499

https://www.poolbegpharma.com

15

Name Title Year Born
Dr. Jeremy Skillington Ph.D. CEO & Director NA
Mr. Ian O'Connell CFO & Director NA
Mr. Salim Hamir F.C.A. Company Sec. NA
Mr. Ross Crockett Group Financial Controller NA
Mr. Cathal Martin Friel Executive Chairman of The Board 1964
Dr. Jeremy Skillington Ph.D. CEO & Director 1971
Mr. Ian O'Connell CFO & Director 1987
Carol Dalton Vice President of Investor Relations & Public Relations NA
Mr. Liam Tremble Principal Scientist NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…